77.10
-3.20 (-3.99%)
| Previous Close | 80.30 |
| Open | 82.00 |
| Volume | 25,884,761 |
| Avg. Volume (3M) | 25,602,537 |
| Market Cap | 126,301,364,224 |
| Price / Earnings (Forward) | 263.16 |
| Price / Sales | 12.22 |
| Price / Book | 8.83 |
| 52 Weeks Range | |
| Earnings Date | 26 Aug 2025 - 1 Sep 2025 |
| Profit Margin | -1.00% |
| Operating Margin (TTM) | 2.85% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | 56.10% |
| Total Debt/Equity (MRQ) | 21.58% |
| Current Ratio (MRQ) | 2.35 |
| Operating Cash Flow (TTM) | 1.29 B |
| Levered Free Cash Flow (TTM) | -113.22 M |
| Return on Assets (TTM) | -0.82% |
| Return on Equity (TTM) | -0.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | INNOVENT BIO | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| INNOVENT BIO | 126 B | - | - | 8.83 |
| AKESO | 88 B | - | - | 11.02 |
| WUXI BIO | 104 B | - | 30.18 | 2.24 |
| SINO BIOPHARM | 102 B | 1.26% | 51.73 | 2.65 |
| PHARMARON | 47 B | 1.23% | 15.04 | 1.88 |
| BEIGENE | 221 B | - | - | 8.31 |
|
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| % Held by Insiders | 6.72% |
| % Held by Institutions | 41.42% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |